JUBLPHARMA.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 08:42):

Stats
Šios dienos apimtis	53 680.00
Vidutinė apimtis	555 110
Rinkos kapitalizacija	109.20B
EPS	INR0 ( 2024-02-01 )
Kita pelno data	( INR0 ) 2024-05-27
Last Dividend	INR5.00 ( 2023-08-10 )
Next Dividend	INR0 ( N/A )
P/E	288.07
ATR14	INR0.417 (0.06%)

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: -0.59 (weak negative)

Signal:(44.901) Neutral

Jubilant Pharmova Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Jubilant Pharmova Limited Koreliacija - Valiuta/Žaliavos

-0.13
( neutral )

-0.28
( neutral )

-0.46
( neutral )

0.45
( neutral )

-0.24
( neutral )

0.50
( weak )

Jubilant Pharmova Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR62.19B
Bruto pelnas:	INR43.41B (69.80 %)
EPS:	INR-3.83

FY	2022
Pajamos:	INR62.19B
Bruto pelnas:	INR43.41B (69.80 %)
EPS:	INR-3.83

FY	2022
Pajamos:	INR60.59B
Bruto pelnas:	INR42.72B (70.51 %)
EPS:	INR26.00

FY	2021
Pajamos:	INR59.64B
Bruto pelnas:	INR42.10B (70.60 %)
EPS:	INR52.48

Financial Reports:

No articles found.

Jubilant Pharmova Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Jubilant Pharmova Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 1.198 - low (50.00%) | Divividend Growth Potential Score: 2.80 - Decrease likely (44.01%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.857	2003-09-18
Last Dividend	INR5.00	2023-08-10
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	INR57.64	--
Avg. Dividend % Per Year	0.70%	--
Score	1.6	--
Div. Sustainability Score	1.198
Div.Growth Potential Score	2.80
Div. Directional Score	1.999	--

Next Divdend (Est)
(2024-06-03)

INR5.22 Estimate 3.15 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR3.00	0.37%
2019	INR4.50	0.63%
2020	INR5.00	0.94%
2021	INR5.00	0.78%
2022	INR5.00	0.85%
2023	INR5.00	1.38%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SILINV.NS	Dividend Junior	2023-08-18	Annually	23	0.63%
MBAPL.NS	Dividend Junior	2023-09-18	Annually	8	0.44%
GUJAPOLLO.NS	Ex Dividend Junior	2023-09-22	Annually	18	0.48%
BAYERCROP.NS	Dividend Junior	2023-08-03	Annually	15	1.25%
PREMIERPOL.NS	Dividend Junior	2023-09-11	Sporadic	9	0.39%
KAMDHENU.NS	Dividend Junior	2023-08-14	Sporadic	17	0.32%
EDELWEISS.NS	Dividend Junior	2023-09-18	Annually	17	2.38%
ADSL.NS	Dividend Junior	2023-08-10	Sporadic	16	0.91%
STERTOOLS.NS	Dividend Junior	2023-09-11	Annually	19	0.38%
NAHARCAP.NS	No Dividend Player	2023-09-08	Annually	17	0.70%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00577	1.500	9.88	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.00701	1.500	-1.033	-1.550	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.512	1.000	-0.551	-0.551	[3 - 30]
operatingCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.673	1.000	2.11	2.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.0588	1.000	-0.825	-0.825	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.198

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	286.36	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00701	2.50	-0.664	-1.550	[0.1 - 1.5]
freeCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.735	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-41.30	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0862	1.000	-0.345	0	[0.1 - 0.5]
Total Score				2.80

Jubilant Pharmova Limited

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.